Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy
Unknown statusPhase 2, Phase 3NCT04429893
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Modified radical mastectomy may be associated with severe post-operative pain, leading to chronic pain syndrome which usually requires optimal perioperative pain management.
Study details
- Official title
- Effectiveness of Adding Magnesium Sulphate to Bupivicaine in Ultrasound Guided Serratus Anterior Plane Block in Patients Undergoing Modified Radical Mastectomy
- Conditions
- Cancer Breast
- Chronic Pain Syndrome
- Interventions
- Drug: magnesium sulphate
- Drug: bupivicaine
- Sponsor
- Alexandria University
- Start date
- 2022-01-01
- Primary completion
- 2022-09
- Sex
- Female
- Age range
- from 20 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult female patients * American Society Of Anesthesiologists (ASA) class I or II * scheduled for elective unilateral modified radical mastectomy Exclusion Criteria * patient refusal * bilateral breast surgery * coagulation disorders * body mass index\> 35 * allergy to local anaesthetics or magnesium sulphate * severe respiratory or cardiac disorders * pre-existing neurological deficits * liver or renal insufficiency
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04429893